Log in

NYSE:ZBHZimmer Biomet Stock Price, Forecast & News

$123.40
+1.40 (+1.15 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$121.16
Now: $123.40
$123.60
50-Day Range
$92.01
MA: $115.23
$126.60
52-Week Range
$74.37
Now: $123.40
$161.11
Volume1.03 million shs
Average Volume1.70 million shs
Market Capitalization$25.47 billion
P/E Ratio68.18
Dividend Yield0.78%
Beta1.32
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Read More
Zimmer Biomet logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 3.3Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

3.09 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone574-267-6131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.98 billion
Cash Flow$13.14 per share
Book Value$60.25 per share

Profitability

Net Income$1.13 billion

Miscellaneous

Employees19,900
Market Cap$25.47 billion
Next Earnings Date7/24/2020 (Estimated)
OptionableOptionable

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

How has Zimmer Biomet's stock been impacted by COVID-19 (Coronavirus)?

Zimmer Biomet's stock was trading at $111.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZBH stock has increased by 11.0% and is now trading at $123.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zimmer Biomet?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 5 hold ratings, 20 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zimmer Biomet.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for Zimmer Biomet.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) announced its earnings results on Monday, May, 11th. The medical equipment provider reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.53 by $0.17. The medical equipment provider had revenue of $1.78 billion for the quarter, compared to analysts' expectations of $1.79 billion. Zimmer Biomet had a net margin of 4.84% and a return on equity of 13.29%. The firm's revenue was down 9.7% on a year-over-year basis. During the same quarter last year, the company earned $1.87 earnings per share. View Zimmer Biomet's earnings history.

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Tuesday, March 10th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.24 per share on Thursday, April 30th. This represents a $0.96 annualized dividend and a yield of 0.78%. The ex-dividend date is Thursday, March 26th. View Zimmer Biomet's dividend history.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.768-1.788 billion, compared to the consensus revenue estimate of $1.93 billion.

What price target have analysts set for ZBH?

27 equities research analysts have issued 12-month price objectives for Zimmer Biomet's stock. Their forecasts range from $115.00 to $177.00. On average, they expect Zimmer Biomet's share price to reach $145.67 in the next year. This suggests a possible upside of 18.0% from the stock's current price. View analysts' price targets for Zimmer Biomet.

Has Zimmer Biomet been receiving favorable news coverage?

News stories about ZBH stock have trended negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zimmer Biomet earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutZimmer Biomet.

Who are some of Zimmer Biomet's key competitors?

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Walt Disney (DIS), AT&T (T), Cisco Systems (CSCO), Intel (INTC), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and Verizon Communications (VZ).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the following people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 57)
  • Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.39%), Massachusetts Financial Services Co. MA (5.15%), State Street Corp (4.14%), JPMorgan Chase & Co. (4.01%), Invesco Ltd. (3.96%) and Capital Research Global Investors (3.80%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Aure Bruneau, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Didier Deltort, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View institutional ownership trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., The Manufacturers Life Insurance Company , Alliancebernstein L.P., Invesco Ltd., Nuveen Asset Management LLC, Balyasny Asset Management LLC, and JPMorgan Chase & Co.. Company insiders that have sold Zimmer Biomet company stock in the last year include Aure Bruneau, Chad F Phipps, Didier Deltort, and Sang Yi. View insider buying and selling activity for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Johnson Investment Counsel Inc., Primecap Management Co. CA, Franklin Resources Inc., AXA, Thrivent Financial for Lutherans, Swiss National Bank, and Reinhart Partners Inc.. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson, and Syed A Jafry. View insider buying and selling activity for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $123.40.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $25.47 billion and generates $7.98 billion in revenue each year. The medical equipment provider earns $1.13 billion in net income (profit) each year or $7.87 on an earnings per share basis. Zimmer Biomet employs 19,900 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.